ImmunoGen, Inc. (IMGN) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
830 WINTER ST WALTHAM, MA 02451 |
| State of Incorp. | MA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 571,987 | 201,249 | 275,138 | 309,511 | 373,874 | 437,661 | |||
| Cash and cash equivalent | 571,987 | 201,249 | 275,138 | 309,511 | 373,874 | 437,661 | |||
| Receivables | 71,506 | 25,667 | 13,814 | 738 | 2,783 | 4,833 | |||
| Inventory, net of allowances, customer advances and progress billings | 3,233 | 614 | |||||||
| Inventory | 3,233 | 614 | |||||||
| Other undisclosed current assets | 22,547 | 16,334 | 15,169 | 20,167 | 17,267 | 14,224 | |||
| Total current assets: | 669,273 | 243,864 | 304,121 | 330,416 | 393,924 | 456,718 | |||
| Noncurrent Assets | |||||||||
| Inventory, Noncurrent | 17,981 | 16,291 | 16,196 | ||||||
| Operating lease, right-of-use asset | 8,997 | 9,627 | 10,231 | 10,809 | 11,361 | 11,888 | |||
| Property, plant and equipment | 3,776 | 4,067 | 4,377 | 4,474 | 4,334 | 4,431 | |||
| Other noncurrent assets | 14,300 | 14,496 | 14,011 | 13,100 | 12,676 | 8,672 | |||
| Total noncurrent assets: | 45,054 | 44,481 | 44,815 | 28,383 | 28,371 | 24,991 | |||
| TOTAL ASSETS: | 714,327 | 288,345 | 348,936 | 358,799 | 422,295 | 481,709 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 65,467 | 74,958 | 95,247 | 84,556 | 58,793 | 48,198 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 8,621 | 4,960 | 3,408 | ||
| Accounts payable | 18,441 | 32,260 | 45,353 | 20,178 | 17,245 | 16,060 | |||
| Accrued liabilities | 47,026 | 42,698 | 49,894 | 55,757 | 36,588 | 28,730 | |||
| Deferred revenue | 14,389 | 13,444 | 13,856 | 15,079 | 15,636 | 23,417 | |||
| Other undisclosed current liabilities | 13,846 | 13,227 | 12,755 | 4,007 | 12,642 | 12,503 | |||
| Total current liabilities: | 93,702 | 101,629 | 121,858 | 103,642 | 87,071 | 84,118 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 12,217 | 13,254 | 14,263 | ||||||
| Liabilities, other than long-term debt | 39,437 | 44,404 | 47,803 | 39,032 | 44,077 | 47,370 | |||
| Deferred revenue | 30,217 | 34,055 | 36,355 | 38,732 | 43,611 | 46,694 | |||
| Other liabilities | 300 | 300 | 300 | 300 | 466 | 676 | |||
| Operating lease, liability | 8,920 | 10,049 | 11,148 | 12,217 | 13,254 | 14,263 | |||
| Other undisclosed noncurrent liabilities | 90,346 | 20,394 | 23,449 | 25,901 | 28,062 | 29,490 | |||
| Total noncurrent liabilities: | 129,783 | 64,798 | 71,252 | 77,150 | 85,393 | 91,123 | |||
| Total liabilities: | 223,485 | 166,427 | 193,110 | 180,792 | 172,464 | 175,241 | |||
| Equity | |||||||||
| Equity, attributable to parent | 490,842 | 121,918 | 155,826 | 178,007 | 249,831 | 306,468 | |||
| Common stock | 2,374 | 2,261 | 2,260 | 2,208 | 2,206 | 2,205 | |||
| Additional paid in capital | 2,227,802 | 1,854,743 | 1,847,638 | 1,810,863 | 1,804,934 | 1,799,551 | |||
| Accumulated deficit | (1,739,334) | (1,735,086) | (1,694,072) | (1,635,064) | (1,557,309) | (1,495,288) | |||
| Total equity: | 490,842 | 121,918 | 155,826 | 178,007 | 249,831 | 306,468 | |||
| TOTAL LIABILITIES AND EQUITY: | 714,327 | 288,345 | 348,936 | 358,799 | 422,295 | 481,709 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 83,153 | 49,869 | 41,167 | 15,375 | 14,162 | 38,078 | ||
| Gross profit: | 83,153 | 49,869 | 41,167 | 15,375 | 14,162 | 38,078 | ||
| Operating expenses | (87,342) | (92,262) | (100,726) | (92,804) | (75,215) | (60,930) | ||
| Operating income (loss): | (4,189) | (42,393) | (59,559) | (77,429) | (61,053) | (22,852) | ||
| Nonoperating income (expense) | 5,215 | 2,232 | 2,740 | 541 | 110 | (44) | ||
| Investment income, nonoperating | 5,223 | 2,169 | 2,158 | 1,539 | 590 | 54 | ||
| Other nonoperating income (expense) | (8) | 63 | 582 | (998) | (480) | (98) | ||
| Interest and debt expense | ||||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 1,026 | (40,161) | (56,819) | (76,888) | (60,943) | (22,896) | ||
| Other undisclosed loss from continuing operations before income taxes | (4,397) | (4,165) | ||||||
| Income (loss) from continuing operations before income taxes: | (3,371) | (40,161) | (60,984) | (76,888) | (60,943) | (22,896) | ||
| Income tax expense (benefit) | (877) | |||||||
| Other undisclosed loss from continuing operations | (1,218) | |||||||
| Income (loss) from continuing operations: | (4,248) | (40,161) | (62,202) | (76,888) | (60,943) | (22,896) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (76,888) | (60,943) | (22,896) | |
| Other undisclosed net income (loss) | (853) | 3,194 | (1,249) | |||||
| Net income (loss): | (4,248) | (41,014) | (59,008) | (76,888) | (60,943) | (24,145) | ||
| Other undisclosed net loss attributable to parent | (867) | (1,078) | ||||||
| Net income (loss) attributable to parent: | (4,248) | (41,014) | (59,008) | (77,755) | (62,021) | (24,145) | ||
| Other undisclosed net loss available to common stockholders, basic | ||||||||
| Net income (loss) available to common stockholders, diluted: | (4,248) | (41,014) | (59,008) | (77,755) | (62,021) | (24,145) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (4,248) | (41,014) | (59,008) | (76,888) | (60,943) | (24,145) | ||
| Comprehensive income (loss): | (4,248) | (41,014) | (59,008) | (76,888) | (60,943) | (24,145) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (867) | (1,078) | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (4,248) | (41,014) | (59,008) | (77,755) | (62,021) | (24,145) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.